Diabetes and cancer: a consensus report

Edward Giovannucci, David M Harlan, Michael C Archer, Richard M Bergenstal, Susan M Gapstur, Laurel A Habel, Michael Pollak, Judith G Regensteiner, Douglas Yee, Edward Giovannucci, David M Harlan, Michael C Archer, Richard M Bergenstal, Susan M Gapstur, Laurel A Habel, Michael Pollak, Judith G Regensteiner, Douglas Yee

Abstract

Epidemiologic evidence suggests that cancer incidence is associated with diabetes as well as certain diabetes risk factors and diabetes treatments. This consensus statement of experts assembled jointly by the American Diabetes Association and the American Cancer Society reviews the state of science concerning 1) the association between diabetes and cancer incidence or prognosis, 2) risk factors common to both diabetes and cancer, 3) possible biologic links between diabetes and cancer risk, and 4) whether diabetes treatments influence risk of cancer or cancer prognosis. In addition, key unanswered questions for future research are posed.

References

    1. World Cancer Report 2008 [article online], 2008. Boyle P, Bernard L. Eds. Cedex, France, World Health Organization, International Agency for Research on Cancer. Available from Accessed 1 April 2010
    1. IDF Diabetes Atlas [article online], 2009. 4th ed Brussels, Belgium, International Diabetes Federation; Available from Accessed 1 April 2010
    1. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007 [article online], 2008. Atlanta, Georgia, Centers for Disease Control and Prevention. Available from Accessed 1 April 2010
    1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747–1757
    1. Joslin EP, Lombard HL, Burrows RE, Manning MD: Diabetes and cancer. N Engl J Med 1959; 260: 486–488
    1. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R: Diabetes and cancer. Endocr Relat Cancer 2009; 16: 1103–1123
    1. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ: Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9: 1039–1047
    1. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL: Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300: 2754–2764
    1. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE: The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008; 109: 389–395
    1. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS: Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 2009; 27: 176–185
    1. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ: Global Cancer Facts & Figures 2007. Atlanta, Georgia, American Cancer Society, 2007
    1. Rosenbloom AL, Joe JR, Young RS, Winter WE: Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999; 22: 345–354
    1. SEARCH for Diabetes in Youth Study Group. Liese AD, D'Agostino RB, Jr, Hamman RF, Kilgo PD, Lawrence JM, Liu LL, Loots B, Linder B, Marcovina S, Rodriguez B, Standiford D, Williams DE: The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006; 118: 1510–1518
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225–249, 2009
    1. Pinheiro SP, Holmes MD, Pollak MN, Barbieri RL, Hankinson SE: Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev 2005; 14: 2147–2153
    1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–1638
    1. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective [article online], 2007. London, World Cancer Research Fund, American Institute for Cancer Research; Available from Accessed 1 April 2010
    1. Schienkiewitz A, Schulze MB, Hoffmann K, Kroke A, Boeing H: Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 2006; 84: 427–433
    1. Abdul-Ghani MA, Sabbah M, Muati B, Dakwar N, Kashkosh H, Minuchin O, Vardi P, Raz I: High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. Isr Med Assoc J 2005; 7: 143–147
    1. Wei M, Gaskill SP, Haffner SM, Stern MP: Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans–a 7-year prospective study. Obes Res 1997; 5: 16–23
    1. Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjønneland A, Halkjaer J, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Guernec G, Bergmann MM, Linseisen J, Becker N, Trichopoulou A, Trichopoulos D, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, Bueno-de-Mesquita HB, Boshuizen HC, Van Guelpen B, Palmqvist R, Berglund G, Gonzalez CA, Dorronsoro M, Barricarte A, Navarro C, Martinez C, Quirós JR, Roddam A, Allen N, Bingham S, Khaw KT, Ferrari P, Kaaks R, Slimani N, Riboli E: Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006; 98: 920–931
    1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DMDiabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403
    1. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J: Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29: 2102–2107
    1. Morisset AS, St-Yves A, Veillette J, Weisnagel SJ, Tchernof A, Robitaille J: Prevention of gestational diabetes mellitus: a review of studies on weight management. Diabete Metab Res Rev 2010; 26: 17–25
    1. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE: Adult weight change and risk of postmenopausal breast cancer. JAMA 2006; 296: 193–201
    1. Renehan AG: Bariatric surgery, weight reduction, and cancer prevention. Lancet Oncol 2009; 10: 640–641
    1. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I: Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248–256
    1. Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, Mitchell P, Brand-Miller JC: Glycemic index, glycemic load, and chronic disease risk–a meta-analysis of observational studies. Am J Clin Nutr 2008; 87: 627–637
    1. Kushi LH, Byers T, Doyle C, Bandera EV, McCullough M, McTiernan A, Gansler T, Andrews KS, Thun MJAmerican Cancer Society 2006 Nutrition and Physical Activity Guidelines Advisory Committee American Cancer Society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2006; 56: 254–281
    1. Tomuta V, Wylie-Rosett J: Nutritional management of diabetes in diabetes and exercise. In Exercise and Diabetes. Regensteiner JG, Reusch JEB, Steward KJ, Veves A. Eds. New York, Humana Press, 2009; p. 231–262
    1. Kastorini CM, Panagiotakos DB: Dietary patterns and prevention of type 2 diabetes: from research to clinical practice; a systematic review. Curr Diabetes Rev 2009; 5: 221–227
    1. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa MFinnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350
    1. Krishnan S, Rosenberg L, Singer M, Hu FB, Djoussé L, Cupples LA, Palmer JR: Glycemic index, glycemic load, and cereal fiber intake and risk of type 2 diabetes in US black women. Arch Intern Med 2007; 167: 2304–2309
    1. Kabat GC, Shikany JM, Beresford SA, Caan B, Neuhouser ML, Tinker LF, Rohan TE: Dietary carbohydrate, glycemic index, and glycemic load in relation to colorectal cancer risk in the Women's Health Initiative. Cancer Causes Control 2008; 19: 1291–1298
    1. George SM, Mayne ST, Leitzmann MF, Park Y, Schatzkin A, Flood A, Hollenbeck A, Subar AF: Dietary glycemic index, glycemic load, and risk of cancer: a prospective cohort study. Am J Epidemiol 2009; 169: 462–472
    1. Lee IM: Physical activity and cancer prevention–data from epidemiologic studies. Med Sci Sports Exerc 2003; 35: 1823–1827
    1. Friedenreich CM, Orenstein MR: Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 2002; 132: 3456S–3464S
    1. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA: Physical activity and survival after breast cancer diagnosis. JAMA 2005; 293: 2479–2486
    1. Meyerhardt JA, Giovannucci EL, Holmes MD, Chan AT, Chan JA, Colditz GA, Fuchs CS: Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 2006; 24: 3527–3534
    1. Physical Activity Guidelines Advisory Committee Report, [article online], 2008. Washington, DC, U.S. Department of Health and Human Services; Available from Accessed 1 April 2010
    1. Mackay J, Jemal A, Lee NC, Parkin DM: The Cancer Atlas. Atlanta, Georgia, American Cancer Society, 2006
    1. Foy CG, Bell RA, Farmer DF, Goff DC, Jr, Wagenknecht LE: Smoking and incidence of diabetes among U.S. adults: findings from the Insulin Resistance Atherosclerosis Study. Diabetes Care 2005; 28: 2501–2507
    1. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J: Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007; 298: 2654–2664
    1. Haire-Joshu D, Glasgow RE, Tibbs TL: Smoking and diabetes. Diabetes Care 1999; 22: 1887–1898
    1. Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano VWHO International Agency for Research on Cancer Monograph Working Group A review of human carcinogens–Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009; 10: 1033–1034
    1. Howard AA, Arnsten JH, Gourevitch MN: Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med 2004; 140: 211–219
    1. Baliunas DO, Taylor BJ, Irving H, Roerecke M, Patra J, Mohapatra S, Rehm J: Alcohol as a risk factor for type 2 diabetes: A systematic review and meta-analysis. Diabetes Care 2009; 32: 2123–2132
    1. Look AHEAD Research Group. Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K, Haffner SM, Harrison B, Hill JO, Horton ES, Jakicic J, Jeffery RW, Johnson KC, Kahn S, Kelley DE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montgomery B, Nathan DM, Patricio J, Peters A, Redmon JB, Reeves RS, Ryan DH, Safford M, Van Dorsten B, Wadden TA, Wagenknecht L, Wesche-Thobaben J, Wing RR, Yanovski SZ: Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30: 1374–1383
    1. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915–928
    1. Denley A, Carroll JM, Brierley GV, Cosgrove L, Wallace J, Forbes B, Roberts CT, Jr.: Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol Cell Biol 2007; 27: 3569–3577
    1. Zhang H, Pelzer AM, Kiang DT, Yee D: Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007; 67: 391–397
    1. Mardilovich K, Pankratz SL, Shaw LM: Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal 2009; 7: 14.
    1. Clemmons DR, Maile LA, Ling Y, Yarber J, Busby WH: Role of the integrin alphaVbeta3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress. Growth Horm IGF Res 2007; 17: 265–270
    1. Giovannucci E: Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131: 3109S–3120S
    1. Ooi GT, Tseng LY, Tran MQ, Rechler MM: Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. Mol Endocrinol 1992; 6: 2219–2228
    1. Powell DR, Suwanichkul A, Cubbage ML, DePaolis LA, Snuggs MB, Lee PD: Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J Biol Chem 1991; 266: 18868–18876
    1. Renehan AG, Frystyk J, Flyvbjerg A: Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006; 17: 328–336
    1. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H: Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabete Metab Res Rev 2009; 25: 41–49
    1. Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, Vannelli GB, Brand R, Goldfine ID, Vigneri R: Elevated insulin receptor content in human breast cancer. J Clin Invest 1990; 86: 1503–1510
    1. Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ: Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 2007; 106: 39–47
    1. Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R: Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 1997; 109: 565–571
    1. Tamimi RM, Byrne C, Colditz GA, Hankinson SE: Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2007; 99: 1178–1187
    1. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM: Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998; 52: 227–237
    1. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE: Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68: 10238–10246
    1. Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579–591
    1. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029–1033
    1. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA, Jr, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N: Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009; 325: 1555–1559
    1. Heuson JC, Legros N: Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res 1972; 32: 226–232
    1. van Kruijsdijk RC, van der Wall E, Visseren FL: Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009; 18: 2569–2578
    1. Ulisse S, Baldini E, Sorrenti S, D'Armiento M: The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009; 9: 32–71
    1. Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798–809
    1. Kalaany NY, Sabatini DM: Tumours with PI3K activation are resistant to dietary restriction. Nature 2009; 458: 725–731
    1. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M: Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197–208
    1. Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M: Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 2008; 15: 833–839
    1. Pollak M: Do cancer cells care if their host is hungry? Cell Metab 2009; 9: 401–403
    1. Defronzo RA: Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773–795
    1. Jabbour S: Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both? Int J Clin Pract 2008; 62: 845–847
    1. Bergenstal RM, Bailey CJ, Kendall DM: Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications. Am J Med 2010; 123: 374.e9–374.e18
    1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman BAmerican Diabetes Association, European Association for Study of Diabetes Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203
    1. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642–1646
    1. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269–10273
    1. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8: 909–915
    1. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8: 2031–2040
    1. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804–10812
    1. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA: The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009; 8: 88–96
    1. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69: 7507–7511
    1. Oliveras-Ferraros C, Vazquez-Martin A, Menendez JA: Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle 2009; 8: 1633–1636
    1. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, Franceschi C: Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005; 40: 685–693
    1. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304–1305
    1. Bowker SL, Majumdar SR, Veugelers P, Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254–258
    1. Currie CJ, Poole CD, Gale EA: The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766–1777
    1. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E: Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009; 46: 279–284
    1. Wright JL, Stanford JL: Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009; 20: 1617–1622
    1. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ: Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33: 322–326
    1. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297–3302
    1. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A: Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev 2009; 18: 701–705
    1. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T: Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86: 2170–2177
    1. Panigrahy D, Huang S, Kieran MW, Kaipainen A: PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 2005; 4: 687–693
    1. Ondrey F: Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 2009; 15: 2–8
    1. Clay CE, Namen AM, Atsumi G, Trimboli AJ, Fonteh AN, High KP, Chilton FH: Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. J Investig Med 2001; 49: 413–420
    1. Clay CE, Monjazeb A, Thorburn J, Chilton FH, High KP: 15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells. J Lipid Res 2002; 43: 1818–1828
    1. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 2001; 61: 6213–6218
    1. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B: Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007; 1771: 1065–1081
    1. Koro C, Barrett S, Qizilbash N: Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 485–492
    1. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP: Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25: 1476–1481
    1. Ramos-Nino ME, MacLean CD, Littenberg B: Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med 2007; 5: 17.
    1. Monami M, Lamanna C, Marchionni N, Mannucci E: Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 2008; 31: 1455–1460
    1. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP: Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003; 79: 391–397
    1. A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARy Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy [clinical trial], 2008. Clinical trial reg. no. NCT00603941, Accessed 1 April 2010
    1. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G: Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745–1754
    1. Currie CJ: The longest ever randomised controlled trial of insulin glargine: study design and HbA(1c) findings. Diabetologia 2009; 52: 2234–2235
    1. Butler PC: Insulin glargine controversy: a tribute to the editorial team at Diabetologia. Diabetes 2009; 58: 2427–2428
    1. Colhoun HMSDRN Epidemiology Group Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52: 1755–1765
    1. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT: Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732–1744
    1. Gerstein HC: Does insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA 2010; 303: 446–447
    1. Smith U, Gale EA: Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1699–1708
    1. Pollak M, Russell-Jones D: Insulin analogues and cancer risk: cause for concern or cause for célèbre? Int J Clin Pract 2010; 64: 628–636
    1. Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP, Hramiak I, Johnston P, Davis M: Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009; 52: 1971–1973
    1. The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) [registered clinical trial], 2009. Clinical trial reg. no. NCT00069784, Accessed 5 April 2010
    1. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D: Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 2009; 16: 429–441
    1. Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, Trüb T: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999–1005
    1. Liefvendahl E, Arnqvist HJ: Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 2008; 40: 369–374
    1. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M: Insulin receptor expression by human prostate cancers. Prostate 2009; 69: 33–40

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera